Merus NV Announces Planned Public Offering of Common Shares to Fund Clinical Development and Research Expansion

Reuters
05 Jun
Merus NV Announces Planned Public Offering of Common Shares to Fund Clinical Development and Research Expansion

Merus N.V., a biotechnology company specializing in innovative oncology treatments, has announced the launch of a public offering of its common shares. All shares will be offered by Merus, with the company planning to provide underwriters a 30-day option to purchase up to an additional 15% of the offered shares. The offering is contingent upon market and other conditions, and there is no assurance regarding the timing, size, or terms of completion. Merus is known for developing multispecific full-length antibodies and antibody-drug conjugates, including Biclonics®, Triclonics®, and ADClonics®.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merus NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9463780-de) on June 05, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10